IP Library Granted Patent US 7,790,862
Granted Patent B2
US 7,790,862 · App. 11/762,738 · Granted Sep 7, 2010

IL-17 and IL-23 antagonists and methods of using the same

Assignee: ZymoGenetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,862
App. No.
11/762,738
Granted
Sep 7, 2010
Kind
B2
Abstract

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Claims (22)

1. An antibody that binds a polypeptide consisting of IL-23 (SEQ ID NO: 4), wherein the antibody comprises:

a) a light chain variable region comprising:

i) a light chain CDR1 comprising the amino acid sequence from 23 to 36 of SEQ ID NO: 1014; and

ii) a light chain CDR2 comprising the amino acid sequence from 52 to 58 of SEQ ID NO: 1014; and

iii) a light chain CDR3 comprising the amino acid sequence from 91 to 102 of SEQ ID NO: 1014; and

b) a heavy chain variable region comprising:

i) a heavy chain CDR1 comprising the amino acid sequence from 31 to 35 of SEQ ID NO: 1015; and

ii) a heavy chain CDR2 comprising the amino acid sequence from 50 to 66 of SEQ ID NO: 1015; and

iii) a heavy chain CDR3 comprising the amino acid sequence from 99 to 112 of SEQ ID NO: 1015.

2. The antibody of claim 1 , wherein the antibody is an antibody fragment.

3. The antibody of claim 2 , wherein said antibody fragment is selected from the group consisting of Fv, Fab, Fab′, F(ab) 2 , and F(ab′) 2 .

4. The antibody of claim 1 , wherein the antibody is a single chain molecule.

5. The antibody of claim 1 , wherein the antibody is a bispecific molecule that also binds IL-17A (SEQ ID NO:2).

6. An antibody that binds a polypeptide consisting of SEQ ID NO: 4, wherein the antibody comprises a light chain variable region comprising SEQ ID NO: 1014 and a heavy chain variable region comprising SEQ ID NO: 1015.

7. The antibody of claim 6 , wherein the antibody is an antibody fragment.

8. The antibody of claim 7 , wherein said antibody fragment is selected from the group consisting of Fv, Fab, Fab′, F(ab) 2 , and F(ab′) 2 .

9. The antibody of claim 6 , wherein the antibody is a single chain molecule.

10. The antibody of claim 6 , wherein the antibody is a bispecific molecule that also binds IL-17A (SEQ ID NO:2).

11. A monoclonal antibody or fragment thereof that binds an epitope consisting of amino acid residues 55 to 66 of SEQ ID NO: 4.

12. A monoclonal antibody or fragment thereof that binds an epitope consisting of amino acid residues 137 to 146 of SEQ ID NO: 4.

13. A monoclonal antibody or fragment thereof that binds an epitope consisting of amino acid residues 74 to 85 of SEQ ID NO: 4.

14. A monoclonal antibody or fragment thereof that binds an epitope consisting of amino acid residues 155 to 164 of SEQ ID NO: 4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2007
From: LEWIS, KATHERINE E.; PRESNELL, SCOTT R.; WEST, JAMES W.; MABRY, ROBERT; MEENGS, BRENT; LEVIN, STEVEN D.
To: ZYMOGENETICS, INC.
Reel/Frame 020268/0252 →
Continuity (5)
Provisional Application 6080460200 · Jun 13, 2006
Provisional Application 6082466500 · Sep 6, 2006
Provisional Application 6082827700 · Oct 5, 2006
Provisional Application 6089141000 · Feb 23, 2007
Related Publication 20080095775A1 · Apr 24, 2008